Metabolic Syndrome is defined using a cluster of laboratory and clinical markers that identify increased risk for cardiovascular disease and type II diabetes.  As much as 25% of the adult American population can be classified with this Syndrome depending on the definition of Metabolic Syndrome used.  A number of therapies exist that treat one or more of the components of the syndrome.  Therapeutic products intended for the treatment of Metabolic Syndrome should ideally normalize or improve all of the components of the syndrome and ultimately prevent the development of type II diabetes and reduce cardiovascular risk.

Key to the development of therapies targeting Metabolic Syndrome is an animal model that spontaneously develops the complications associated with the syndrome.  The ZDSD rat currently available for sale from PreClinOmics is such a model.  Current data demonstrates that the ZDSD spontaneously develops obesity, insulin resistance, hyperglycemia, and elevated lipids.  These factors ultimately lead to the development of Type II diabetes in the model as well.  Dietary manipulation can synchronize the expression of these complications.  Studies are ongoing to characterize the cardiovascular risk factors.

Interested researchers are encouraged to contact us to inquire about receiving small cohorts of animals for feasibility studies.  These animals are provided in exchange for payment of shipping charges and control data that may be used to further understand the value of the model.

In brief, male ZDSD rats, maintained on LabDiet 5008, will spontaneously exhibit the following (click to enlarge graphs):

Obesity:

 

Hyperglycemia:

 

Insulin Resistance:

 

Hypertriglyceridemia:

 

Be sure to sign up for our RSS feed to be kept up to date with Service Capabilities, ZDSD and Fatzo.

Similarly, the MSD insulin assay has a broad detection range, needs a sample volume of only 10-ul for a single analysis and has a high assay reproducibility (low CV) for duplicated analyses.    

If you have any Assay needs,  please contact us for analyzing metabolic, inflammatory and many other biomarkers from rodent, canine, swine and human samples by MSD, Luminex, Micro-plate (ELISA and Enzymatic), and clinical analyzer.

At this year’s meeting of the American Society of Nephrology we will be presenting a poster on our ZDSD rat entitled “The ZDSD/Pco Rat, A Type II Diabetic Model for Diabetic Nephropathy Without Leptin or Leptin Receptor Mutations.”    (TH-PO750) Our Dr. Richard Peterson, developer of the ZDF and ZDSD rats, will be at the poster Oct 29^th. 

ASN Poster

Additional information on the ZDSD rat can be found here.

Hope to talk to you soon,
Troy
Director, Sales & Marketing